The US FDA in the Wake of Vioxx - Overcautious or Showing Due Care?
This article was originally published in SRA
People are lining up to accuse the US Food and Drug Administration (FDA) of having become more conservative in its assessment of new pharmaceuticals in the light of recent high-profile safety controversies.
You may also be interested in...
The company is optimistic about a significant portion of eligible patients opting for its newly approved long-acting HIV therapy over daily, oral antiviral therapy.
After reviewing real-world data, the US agency says the decontamination systems should only be used for compatible facemasks and should not be used to clean a mask more than four times.
Under an extensive COVID-19 plan and executive order signed on 21 January, the US president explained how he’ll beef up testing and manufacturing of medtech to fight the virus.